" class="no-js "lang="en-US"> Clearsense Acquires Plug-and-Play AI Analytics Firm - Medtech Alert
Wednesday, February 08, 2023

Clearsense Acquires Plug-and-Play AI Analytics Firm

Clearsense, an AI-powered data analytics platform company that translates healthcare data into highly consumable insights, today announced the acquisition of Compellon, a privately-held, plug-and-play AI analytics company based in Lake Forest, California. The multi-patented Compellon technology uses AI to re-engineer predictive modeling, removing the technical burden from users. The technology is a hand in glove complement to the end-to-end Clearsense platform which cleans, organizes, and enriches data to transform it into ready-to-use, insights that users trust.

Clearsense Co-founder and Chief Innovation Officer Charles Boicey stated, “Compellon’s game changing technology directly supports our mission to rapidly make data analytics nearly as easy as a Google query for clinicians and everyday users.” Boicey added, “With this solution, clinicians and other users can bypass the arduous, time-consuming manual process of testing hypothesis, and see results in hours instead of weeks or more.” The Compellon predictive modeling solution is a cornerstone of the Clearsense advanced analytics and research platform.

Advanced end-to-end solutions like Clearsense are beckoning in a new era of the citizen data scientist in healthcare by empowering everyday users to solve business and clinical problems without the technical expertise previously required. 

People In This Post

Companies In This Post

  1. Tvardi Therapeutics Appoints John Kauh, M.D. as Chief Medical Officer Read more
  2. Exact Sciences Launches OncoExTra™ Cancer Therapy Selection Test in the U.S. Read more
  3. Spectrum Science Receives Strategic Investment from Knox Lane to Fuel Continued Growth Read more
  4. Synergy Health Partners Selects Dr. Richard L. Makowiec as Chief Surgical Officer Read more
  5. TILT Biotherapeutics Announces Final Close of €22 Million Financing Round to Advance to Phase II Oncology Immunotherapy Trials Read more